Purpose: Alternative modalities to optimize pain control after anterior cruciate ligament reconstruction (ACLR) are continually being explored. The purpose of this study was to compare femoral nerve block (FNB) only vs FNB with posterior capsule injection (PCI) of the knee for pain control in patients undergoing ACLR.
Methods: Patients undergoing primary ACLR were randomized to receive either FNB only or FNB with PCI. Following surgery, patient's pain was evaluated in the postoperative care unit (PACU) and at home for 4 days. Pain levels were measured via visual analog scale (VAS) and calculating opioid consumption. Outcomes of interest included postoperative pain levels and opioid consumption.
Results: A total of 42 patients were evaluated, with 21 patients randomized to each study arm. Outcomes showed significant pain reduction in both anterior and posterior knee VAS scores in the PACU in those that received PCI (anterior VAS: 39.6 vs 21.3 (SD = 12.9), p < 0.01; posterior VAS: 25.4 vs 15.3 (SD = 8.05), p = 0.01). Moreover, the PCI group also showed significantly less opioid consumption compared to FNB only (23.5 vs 17.4 pills, p = 0.03). There were no differences found in pain scores between groups in home VAS sores.
Conclusions: These finding suggest the use of arthroscopically assisted injection of local anesthetic to the posterior capsule of the knee significantly reduces early post-operative pain and dramatically reduces the number of opoid medication taken after ACLR.
Level Of Evidence: Prospective, randomized, control trial, Level I.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00167-018-5111-3 | DOI Listing |
Orv Hetil
January 2025
2 Semmelweis Egyetem, Általános Orvostudományi Kar, Aneszteziológiai és Perioperatív Betegellátó Intézet Budapest, Üllői út 78/B, 1082 Magyarország.
Am J Cardiovasc Drugs
January 2025
Pediatric Nephrology, State University of Campinas, São Paulo, Brazil.
Around one-quarter of all patients undergoing cardiac procedures, particularly those on cardiopulmonary bypass, develop cardiac surgery-associated acute kidney injury (CSA-AKI). This complication increases the risk of several serious morbidities and of mortality, representing a significant burden for both patients and the healthcare system. Patients with diminished kidney function before surgery, such as those with chronic kidney disease, are at heightened risk of developing CSA-AKI and have poorer outcomes than patients without preexisting kidney injury who develop CSA-AKI.
View Article and Find Full Text PDFRheumatology (Oxford)
January 2025
The National Axial Spondyloarthritis Society, London, UK.
Cell Mol Biol (Noisy-le-grand)
January 2025
Department of Pharmacology, Faculty of Pharmacy, Mersin University, Mersin, Türkiye.
Increasing evidence suggests that inhibition of receptor-interacting serine/threonine-protein kinase (RIPK) 1/RIPK3/mixed lineage kinase domain-like pseudokinase (MLKL) necrosome has protective effects in vivo models of painful conditions seen in humans associated with inflammation and demyelination in the central nervous system. However, the contribution of RIPK1-driven necroptosis to inflammatory pain remains unknown. Therefore, this study aims to determine the effect of necrostatin (Nec) -1s, a selective RIPK1 inhibitor, on lipopolysaccharide (LPS)-induced inflammatory pain and related underlying mechanisms.
View Article and Find Full Text PDFPak J Pharm Sci
January 2025
Department of Pathobiology and Biomedical Sciences, Muhammad Nawaz Sharif University of Agriculture, Multan, Pakistan/Ali-Ul-Murtaza Department of Rehabilitation Sciences, Muhammad Institute of Medical and Allied Sciences, Multan, Pakistan.
This study aimed to evaluate the efficacy of vinegar-soaked Ficus carica fruits (VSFCF) for managing cholelithiasis in adults. A parallel-group, single-blinded, randomized controlled trial at Noreen Nishat Welfare Hospital, Khanewal, Pakistan, was conducted from December 2023 to February 2024. Fifty adults with ultrasound-confirmed cholelithiasis were randomly assigned to receive either VSFCF (1 g/kg/day) or ursodiol (600 mg/day).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!